Dopavision

Dopavision is redefining therapeutic solutions for ophthalmic and neurological conditions using a unique photobiomodulation method targeting the eye’s blind spot. Our first goal is to develop a clinically validated intervention to slow the progression of myopia (nearsightedness) in children, a serious and growing public health challenge projected to affect nearly half of the global population by 2050. Our ground-breaking approach, MyopiaX, is a clinical-stage technology that administers a non-invasive, light-based intervention via a smartphone app using standard consumer electronics. This approach aims to regulate the eye’s innate growth mechanism to control myopia. MyopiaX aims to offer an accessible and user-friendly therapy, and is accompanied by interactive, age-appropriate content. Rooted in a strong scientific rationale, MyopiaX is undergoing a proof-of-concept clinical trial. Founded in 2017, Dopavision is supported by top-tier international investors and the German government.